Skip to main content
Erschienen in: Osteoporosis International 1/2006

01.01.2006 | Review

Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature

verfasst von: Rachael L. Fleurence, Cynthia P. Iglesias, David J. Torgerson

Erschienen in: Osteoporosis International | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Abstract

Economic evaluations are increasingly being used by decision-makers to estimate the cost-effectiveness of interventions. The objective of this study was to conduct a structured review of economic evaluations of interventions to prevent and treat osteoporosis. Articles were identified independently by two reviewers through searches on MEDLINE, the bibliographies of reviews and identified economic models, and expert opinion, using predefined inclusion and exclusion criteria. Data on country, type and level of interventions, type of fractures, interventions, study population and the authors’ stated conclusions were extracted. Forty-two relevant studies were identified. The majority of studies (71%) were conducted in Sweden, the UK and the US. The main interventions investigated were hormone replacement therapy (27%), bisphosphonates (17%) and combinations of vitamin D and calcium (16%). In 38% of studies, hip fracture was the sole fracture outcome. Eighty-eight percent (88%) of studies investigated female populations only. A relatively large number of economic evaluations were identified in the field of osteoporosis. Major changes have recently occurred in the treatment of this disease, following the publication of the results of the Women’s Health Initiative trial. Methodological developments in economic evaluations, such as the use of probabilistic sensitivity analysis and cost-effectiveness acceptability curves, have also taken place. Such changes are reflected in the studies that were reviewed. The development of economic models should be an iterative process that incorporates new information, whether clinical or methodological, as it becomes available.
Literatur
1.
Zurück zum Zitat Taylor RS, Drummond MF, Salkeld G, Sullivan SD (2004) Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ 329: 972–975CrossRefPubMed Taylor RS, Drummond MF, Salkeld G, Sullivan SD (2004) Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ 329: 972–975CrossRefPubMed
2.
Zurück zum Zitat Fleurence RL, Iglesias CP, Torgerson DJ (2003) Cost-effectiveness of nutritional supplements for the treatment of osteoporosis. In: Bonjour JP, New S (eds) Nutritional aspects of bone health. Royal Society of Chemistry, London, pp 693–708 Fleurence RL, Iglesias CP, Torgerson DJ (2003) Cost-effectiveness of nutritional supplements for the treatment of osteoporosis. In: Bonjour JP, New S (eds) Nutritional aspects of bone health. Royal Society of Chemistry, London, pp 693–708
3.
Zurück zum Zitat Fleurence RL, Iglesias CP, Torgerson DJ (2005) Economic aspects of osteoporosis treatment. In Cooper C, Lindsay R (eds) The prevention and treatment of osteoporosis in the high-risk patient. Martin Dunitz, London, pp 81–102 Fleurence RL, Iglesias CP, Torgerson DJ (2005) Economic aspects of osteoporosis treatment. In Cooper C, Lindsay R (eds) The prevention and treatment of osteoporosis in the high-risk patient. Martin Dunitz, London, pp 81–102
4.
Zurück zum Zitat Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333CrossRefPubMed Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333CrossRefPubMed
5.
Zurück zum Zitat Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, et al (2003) Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA 289:2673–2684CrossRefPubMed Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, et al (2003) Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA 289:2673–2684CrossRefPubMed
6.
Zurück zum Zitat Anderson GL, Limacher M, Assaf AR, Bassford T, et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712CrossRefPubMed Anderson GL, Limacher M, Assaf AR, Bassford T, et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712CrossRefPubMed
7.
Zurück zum Zitat Birks YF, Porthouse J, Addie C, Loughney K, et al (2004) Randomized controlled trial of hip protectors among women living in the community. Osteoporos Int 15:701–706PubMedCrossRef Birks YF, Porthouse J, Addie C, Loughney K, et al (2004) Randomized controlled trial of hip protectors among women living in the community. Osteoporos Int 15:701–706PubMedCrossRef
8.
Zurück zum Zitat Trivedi DP, Doll R, Khaw KT (2003) Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 326:469CrossRefPubMed Trivedi DP, Doll R, Khaw KT (2003) Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 326:469CrossRefPubMed
9.
Zurück zum Zitat Porthouse J, Cockayne S, King C, Saxon L, et al (2005) Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ (in press) Porthouse J, Cockayne S, King C, Saxon L, et al (2005) Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ (in press)
10.
Zurück zum Zitat The RECORD Trial Group (2005). Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet (in press) The RECORD Trial Group (2005). Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet (in press)
11.
Zurück zum Zitat Zethraeus N, Ben Sedrine W, Caulin F, Corcaud S, et al (2002) Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int 13:841–857CrossRefPubMed Zethraeus N, Ben Sedrine W, Caulin F, Corcaud S, et al (2002) Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int 13:841–857CrossRefPubMed
12.
Zurück zum Zitat Coyle D, Cranney A, Lee KM, Welch V, et al (2000) Cost-effectiveness research in osteoporosis. Drug Dev Res 49:135–140CrossRef Coyle D, Cranney A, Lee KM, Welch V, et al (2000) Cost-effectiveness research in osteoporosis. Drug Dev Res 49:135–140CrossRef
13.
Zurück zum Zitat Johannesson M, Jonsson B (1993) Economic evaluation of osteoporosis prevention. Health Policy 24:103–124CrossRefPubMed Johannesson M, Jonsson B (1993) Economic evaluation of osteoporosis prevention. Health Policy 24:103–124CrossRefPubMed
14.
Zurück zum Zitat Sculpher M, Torgerson D, Goeree R, O’Brien BJ (1999) A critical structured review of economic evaluations of interventions for the prevention and treatment of osteoporosis. CHE Discussion Paper 169, University of York, York Sculpher M, Torgerson D, Goeree R, O’Brien BJ (1999) A critical structured review of economic evaluations of interventions for the prevention and treatment of osteoporosis. CHE Discussion Paper 169, University of York, York
15.
Zurück zum Zitat Torgerson DJ, Reid DM (1997) The economics of osteoporosis and its prevention. A review. Pharmacoeconomics 11:126–138PubMedCrossRef Torgerson DJ, Reid DM (1997) The economics of osteoporosis and its prevention. A review. Pharmacoeconomics 11:126–138PubMedCrossRef
16.
Zurück zum Zitat Whittington R, Faulds D (1994) Hormone replacement therapy: II. A pharmacoeconomic appraisal of its role in the prevention of postmenopausal osteoporosis and ischaemic heart disease. Pharmacoeconomics 5:513–554PubMed Whittington R, Faulds D (1994) Hormone replacement therapy: II. A pharmacoeconomic appraisal of its role in the prevention of postmenopausal osteoporosis and ischaemic heart disease. Pharmacoeconomics 5:513–554PubMed
17.
Zurück zum Zitat Cheung AP, Wren BG (1992) A cost-effectiveness analysis of hormone replacement therapy in the menopause. Med J Aust 156:312–316PubMedMathSciNet Cheung AP, Wren BG (1992) A cost-effectiveness analysis of hormone replacement therapy in the menopause. Med J Aust 156:312–316PubMedMathSciNet
18.
Zurück zum Zitat Tosteson AN, Rosenthal DI, Melton III LJ, Weinstein MC (1990) Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 113:594–603PubMed Tosteson AN, Rosenthal DI, Melton III LJ, Weinstein MC (1990) Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 113:594–603PubMed
19.
Zurück zum Zitat Tosteson AN, Weinstein MC (1991) Cost-effectiveness of hormone replacement therapy after the menopause. Bailliere’s Clin Obstetr Gynaecol 5:943–959 Tosteson AN, Weinstein MC (1991) Cost-effectiveness of hormone replacement therapy after the menopause. Bailliere’s Clin Obstetr Gynaecol 5:943–959
20.
Zurück zum Zitat Weinstein MC (1980) Estrogen use in postmenopausal women—costs, risks, and benefits. N Engl J Med 303:308–316PubMedCrossRef Weinstein MC (1980) Estrogen use in postmenopausal women—costs, risks, and benefits. N Engl J Med 303:308–316PubMedCrossRef
21.
Zurück zum Zitat Weinstein MC, Schiff I (1983) Cost-effectiveness of hormone replacement therapy in the menopause. Obstet Gynecol Surv 38:445–455PubMed Weinstein MC, Schiff I (1983) Cost-effectiveness of hormone replacement therapy in the menopause. Obstet Gynecol Surv 38:445–455PubMed
22.
Zurück zum Zitat Weinstein MC, Tosteson AN (1990) Cost-effectiveness of hormone replacement. Ann N Y Acad Sci 592:162–172PubMedADS Weinstein MC, Tosteson AN (1990) Cost-effectiveness of hormone replacement. Ann N Y Acad Sci 592:162–172PubMedADS
23.
Zurück zum Zitat Jonsson B, Kanis J, Dawson A, Oden A, et al (1999) Effect and offset of effect of treatments for hip fracture on health outcomes. Osteoporos Int 10:193–199CrossRefPubMed Jonsson B, Kanis J, Dawson A, Oden A, et al (1999) Effect and offset of effect of treatments for hip fracture on health outcomes. Osteoporos Int 10:193–199CrossRefPubMed
24.
Zurück zum Zitat Kanis JA, Dawson A, Oden A, Johnell O, et al (2001) Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 12:356–361CrossRefPubMed Kanis JA, Dawson A, Oden A, Johnell O, et al (2001) Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 12:356–361CrossRefPubMed
25.
Zurück zum Zitat Zethraeus N, Johannesson M, Jonsson B (1999) A computer model to analyze the cost-effectiveness of hormone replacement therapy. Int J Technol Assess Health Care 15:352–365PubMed Zethraeus N, Johannesson M, Jonsson B (1999) A computer model to analyze the cost-effectiveness of hormone replacement therapy. Int J Technol Assess Health Care 15:352–365PubMed
26.
Zurück zum Zitat Fleurence RL, Torgerson DJ, Reid DM (2002) Cost-effectiveness of hormone replacement therapy for fracture prevention in young postmenopausal women: an economic analysis based on a prospective cohort study. Osteoporos Int 13:637–643CrossRefPubMed Fleurence RL, Torgerson DJ, Reid DM (2002) Cost-effectiveness of hormone replacement therapy for fracture prevention in young postmenopausal women: an economic analysis based on a prospective cohort study. Osteoporos Int 13:637–643CrossRefPubMed
27.
Zurück zum Zitat Buxton MJ, Drummond MF, Van Hout BA, Prince RL, et al (1997) Modelling in economic evaluation: an unavoidable fact of life. Health Econ 6:217–227CrossRefPubMed Buxton MJ, Drummond MF, Van Hout BA, Prince RL, et al (1997) Modelling in economic evaluation: an unavoidable fact of life. Health Econ 6:217–227CrossRefPubMed
28.
Zurück zum Zitat Sculpher M, Fenwick E, Claxton K (2000) Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application. Pharmacoeconomics 17:461–477PubMedCrossRef Sculpher M, Fenwick E, Claxton K (2000) Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application. Pharmacoeconomics 17:461–477PubMedCrossRef
29.
Zurück zum Zitat Tosteson AN, Jonsson B, Grima DT, O’Brien BJ, et al (2001) Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 12:849–857CrossRefPubMed Tosteson AN, Jonsson B, Grima DT, O’Brien BJ, et al (2001) Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 12:849–857CrossRefPubMed
30.
Zurück zum Zitat Borgstrom F, Johnell O, Jonsson B, Zethraeus N, et al (2004) Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 34:1064–1071CrossRefPubMed Borgstrom F, Johnell O, Jonsson B, Zethraeus N, et al (2004) Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 34:1064–1071CrossRefPubMed
31.
Zurück zum Zitat Fleurence RL (2004) The cost-effectiveness of fracture prevention treatments in the elderly. Int J Technol Assess Health Care 20:184–191CrossRefPubMed Fleurence RL (2004) The cost-effectiveness of fracture prevention treatments in the elderly. Int J Technol Assess Health Care 20:184–191CrossRefPubMed
32.
Zurück zum Zitat Iglesias CP, Torgerson DJ, Bearne A, Bose U (2002) The cost utility of bisphosphonate treatment in established osteoporosis. QJM 95:305–311CrossRefPubMed Iglesias CP, Torgerson DJ, Bearne A, Bose U (2002) The cost utility of bisphosphonate treatment in established osteoporosis. QJM 95:305–311CrossRefPubMed
33.
Zurück zum Zitat Kanis JA, Borgstrom F, Johnell O, Jonsson B (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 15:862–871CrossRefPubMed Kanis JA, Borgstrom F, Johnell O, Jonsson B (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 15:862–871CrossRefPubMed
34.
Zurück zum Zitat Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D, Jonsson B (2005) Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 16:15–25CrossRefPubMed Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D, Jonsson B (2005) Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 16:15–25CrossRefPubMed
35.
Zurück zum Zitat Torgerson DJ, Bell-Syer SE (2001) Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 285:2891–2897CrossRefPubMed Torgerson DJ, Bell-Syer SE (2001) Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 285:2891–2897CrossRefPubMed
36.
Zurück zum Zitat Manson JE, Hsia J, Johnson KC, Rossouw JE, et al (2003) Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349:523–534CrossRefPubMed Manson JE, Hsia J, Johnson KC, Rossouw JE, et al (2003) Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349:523–534CrossRefPubMed
37.
Zurück zum Zitat Majumdar SR, Almasi EA, Stafford RS (2004) Promotion and prescribing of hormone therapy after report of harm by the Women’s Health Initiative. JAMA 292:1983–1988CrossRefPubMed Majumdar SR, Almasi EA, Stafford RS (2004) Promotion and prescribing of hormone therapy after report of harm by the Women’s Health Initiative. JAMA 292:1983–1988CrossRefPubMed
38.
Zurück zum Zitat Grady D (2003) Postmenopausal hormones—therapy for symptoms only. N Engl J Med 348:1835–1837CrossRefPubMed Grady D (2003) Postmenopausal hormones—therapy for symptoms only. N Engl J Med 348:1835–1837CrossRefPubMed
39.
Zurück zum Zitat Black DM, Cummings SR, Karpf DB, Cauley JA, et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541CrossRefPubMed Black DM, Cummings SR, Karpf DB, Cauley JA, et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541CrossRefPubMed
40.
Zurück zum Zitat Cummings SR, Eckert S, Krueger KA, Grady D, et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189–2197CrossRefPubMed Cummings SR, Eckert S, Krueger KA, Grady D, et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189–2197CrossRefPubMed
41.
Zurück zum Zitat Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645CrossRefPubMed Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645CrossRefPubMed
42.
Zurück zum Zitat Levis S, Quandt SA, Thompson D, Scott J, et al (2002) Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial. J Am Geriatr Soc 50:409–415CrossRefPubMed Levis S, Quandt SA, Thompson D, Scott J, et al (2002) Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial. J Am Geriatr Soc 50:409–415CrossRefPubMed
43.
Zurück zum Zitat Reginster J, Minne HW, Sorensen OH, Hooper M, et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91CrossRefPubMed Reginster J, Minne HW, Sorensen OH, Hooper M, et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91CrossRefPubMed
44.
Zurück zum Zitat Johnell O, Kanis J, Gullberg G (2001) Mortality, morbidity, and assessment of fracture risk in male osteoporosis. Calcif Tissue Int 69:182–184CrossRefPubMed Johnell O, Kanis J, Gullberg G (2001) Mortality, morbidity, and assessment of fracture risk in male osteoporosis. Calcif Tissue Int 69:182–184CrossRefPubMed
45.
Zurück zum Zitat Segui-Gomez M, Keuffel E, Frick KD (2002) Cost and effectiveness of hip protectors among the elderly. Int J Technol Assess Health Care 18:55–66PubMed Segui-Gomez M, Keuffel E, Frick KD (2002) Cost and effectiveness of hip protectors among the elderly. Int J Technol Assess Health Care 18:55–66PubMed
46.
Zurück zum Zitat Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936PubMedCrossRef Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936PubMedCrossRef
47.
Zurück zum Zitat Stevenson MD, Oakley J, Chilcott JB (2004) Gaussian process modeling in conjunction with individual patient simulation modeling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis. Med Decis Making 24:89–100CrossRefPubMed Stevenson MD, Oakley J, Chilcott JB (2004) Gaussian process modeling in conjunction with individual patient simulation modeling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis. Med Decis Making 24:89–100CrossRefPubMed
48.
Zurück zum Zitat Ankjaer-Jensen A, Johnell O (1996) Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporos Int 6:265–275CrossRefPubMed Ankjaer-Jensen A, Johnell O (1996) Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporos Int 6:265–275CrossRefPubMed
49.
Zurück zum Zitat Armstrong K, Chen TM, Albert D, Randall TC, et al (2001) Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk. Obstet Gynecol 98:996–1003CrossRefPubMed Armstrong K, Chen TM, Albert D, Randall TC, et al (2001) Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk. Obstet Gynecol 98:996–1003CrossRefPubMed
50.
Zurück zum Zitat Brecht JG, Kruse HP, Felsenberg D, Mohrke W, et al (2003) Pharmacoeconomic analysis of osteoporosis treatment with risedronate. Int J Clin Pharmacol Res 23:93–105PubMed Brecht JG, Kruse HP, Felsenberg D, Mohrke W, et al (2003) Pharmacoeconomic analysis of osteoporosis treatment with risedronate. Int J Clin Pharmacol Res 23:93–105PubMed
51.
Zurück zum Zitat Brecht JG, Kruse HP, Mohrke W, Oestreich A, et al (2004) Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Int J Clin Pharmacol Res 24:1–10PubMed Brecht JG, Kruse HP, Mohrke W, Oestreich A, et al (2004) Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Int J Clin Pharmacol Res 24:1–10PubMed
52.
Zurück zum Zitat Colon-Emeric CS, Datta SK, Matchar DB (2003) An economic analysis of external hip protector use in ambulatory nursing facility residents. Age Ageing 32:47–52CrossRefPubMed Colon-Emeric CS, Datta SK, Matchar DB (2003) An economic analysis of external hip protector use in ambulatory nursing facility residents. Age Ageing 32:47–52CrossRefPubMed
53.
Zurück zum Zitat Coyle D, Cranney A, Lee KM (2001) Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation. Pharmacoeconomics 19:565–575PubMedCrossRef Coyle D, Cranney A, Lee KM (2001) Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation. Pharmacoeconomics 19:565–575PubMedCrossRef
54.
Zurück zum Zitat Daly E, Roche M, Barlow D, Gray A, et al (1992) HRT: an analysis of benefits, risks and costs. Br Med Bull 48:368–400PubMed Daly E, Roche M, Barlow D, Gray A, et al (1992) HRT: an analysis of benefits, risks and costs. Br Med Bull 48:368–400PubMed
55.
Zurück zum Zitat Daly E, Vessey MP, Barlow D, Gray A, et al (1996) Hormone replacement therapy in a risk-benefit perspective. Maturitas 23:247–259CrossRefPubMed Daly E, Vessey MP, Barlow D, Gray A, et al (1996) Hormone replacement therapy in a risk-benefit perspective. Maturitas 23:247–259CrossRefPubMed
56.
Zurück zum Zitat Francis RM, Anderson FH, Torgerson DJ (1995) A comparison of the effectiveness and cost of treatment for vertebral fractures in women. Br J Rheumatol 34:1167–1171PubMed Francis RM, Anderson FH, Torgerson DJ (1995) A comparison of the effectiveness and cost of treatment for vertebral fractures in women. Br J Rheumatol 34:1167–1171PubMed
57.
Zurück zum Zitat Garton MJ, Cooper C, Reid D (1997) Perimenopausal bone density screening—will it help prevent osteoporosis? Maturitas 26:35–43CrossRefPubMed Garton MJ, Cooper C, Reid D (1997) Perimenopausal bone density screening—will it help prevent osteoporosis? Maturitas 26:35–43CrossRefPubMed
58.
Zurück zum Zitat Geelhoed E, Harris A, Prince R (1994) Cost-effectiveness analysis of hormone replacement therapy and lifestyle intervention for hip fracture. Aust J Public Health 18:153–160PubMedCrossRef Geelhoed E, Harris A, Prince R (1994) Cost-effectiveness analysis of hormone replacement therapy and lifestyle intervention for hip fracture. Aust J Public Health 18:153–160PubMedCrossRef
59.
Zurück zum Zitat Hart WM, Rubio-Terres C, Burrell A, Aristegui I, et al (2002) Pharmacoeconomic analysis of the treatment of postmenopausal osteoporosis with risedronate or alendronate. Revista Espanola de Enfermedades Metabolicas Oseas 11:97–104 Hart WM, Rubio-Terres C, Burrell A, Aristegui I, et al (2002) Pharmacoeconomic analysis of the treatment of postmenopausal osteoporosis with risedronate or alendronate. Revista Espanola de Enfermedades Metabolicas Oseas 11:97–104
60.
Zurück zum Zitat Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305–314PubMedCrossRef Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305–314PubMedCrossRef
61.
Zurück zum Zitat Jonsson B (1998) Targeting high-risk populations. Osteoporos Int 8 [Suppl 1]:S13–S16 Jonsson B (1998) Targeting high-risk populations. Osteoporos Int 8 [Suppl 1]:S13–S16
62.
Zurück zum Zitat Jonsson B, Christiansen C, Johnell O, Hedbrandt J (1995) Cost-effectiveness of fracture prevention in established osteoporosis. Osteoporos Int 5:136–142CrossRefPubMed Jonsson B, Christiansen C, Johnell O, Hedbrandt J (1995) Cost-effectiveness of fracture prevention in established osteoporosis. Osteoporos Int 5:136–142CrossRefPubMed
63.
Zurück zum Zitat Kanis JA, Brazier JE, Stevenson M, Calvert NW, et al (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 6:1–146PubMed Kanis JA, Brazier JE, Stevenson M, Calvert NW, et al (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 6:1–146PubMed
64.
Zurück zum Zitat Nagata-Kobayashi S, Shimbo T, Fukui T (2002) Cost-effectiveness analysis of screening for osteoporosis in postmenopausal Japanese women. J Bone Miner Metab 20:350–357CrossRefPubMed Nagata-Kobayashi S, Shimbo T, Fukui T (2002) Cost-effectiveness analysis of screening for osteoporosis in postmenopausal Japanese women. J Bone Miner Metab 20:350–357CrossRefPubMed
65.
Zurück zum Zitat Rodriguez EC, Fidalgo Garcia ML, Rubio CS (1999) A cost-effectiveness analysis of alendronate compared to placebo in the prevention of hip fracture. Aten Primaria 24:390–396PubMed Rodriguez EC, Fidalgo Garcia ML, Rubio CS (1999) A cost-effectiveness analysis of alendronate compared to placebo in the prevention of hip fracture. Aten Primaria 24:390–396PubMed
66.
Zurück zum Zitat Rosner AJ, Grima DT, Torrance GW, Bradley C, et al (1998) Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Pharmacoeconomics 14:559–573PubMedCrossRef Rosner AJ, Grima DT, Torrance GW, Bradley C, et al (1998) Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Pharmacoeconomics 14:559–573PubMedCrossRef
67.
Zurück zum Zitat Singh S, Sun H, Anis AH (2004) Cost-effectiveness of hip protectors in the prevention of osteoporosis related hip fractures in elderly nursing home residents. J Rheumatol 31:1607–1613PubMed Singh S, Sun H, Anis AH (2004) Cost-effectiveness of hip protectors in the prevention of osteoporosis related hip fractures in elderly nursing home residents. J Rheumatol 31:1607–1613PubMed
68.
Zurück zum Zitat Torgerson D, Kanis JA (1995) Cost-effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium. QJM 88:135–139PubMed Torgerson D, Kanis JA (1995) Cost-effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium. QJM 88:135–139PubMed
69.
Zurück zum Zitat Torgerson D, Donaldson C, Reid D (1996) Using economics to prioritize research: a case study of randomized trials for the prevention of hip fractures due to osteoporosis. J Health Serv Res Policy 1:141–146PubMed Torgerson D, Donaldson C, Reid D (1996) Using economics to prioritize research: a case study of randomized trials for the prevention of hip fractures due to osteoporosis. J Health Serv Res Policy 1:141–146PubMed
70.
Zurück zum Zitat Visentin P, Ciravegna R, Fabris F (1997) Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy. Maturitas 26:185–192CrossRefPubMed Visentin P, Ciravegna R, Fabris F (1997) Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy. Maturitas 26:185–192CrossRefPubMed
71.
Zurück zum Zitat Waldegger L, Cranney A, Man-Son-Hing M, Coyle D (2003) Cost-effectiveness of hip protectors in institutional dwelling elderly. Osteoporos Int 14:243–250PubMed Waldegger L, Cranney A, Man-Son-Hing M, Coyle D (2003) Cost-effectiveness of hip protectors in institutional dwelling elderly. Osteoporos Int 14:243–250PubMed
72.
Zurück zum Zitat Willis M, Odegaard K, Persson U, Mellstrom D, et al (2001) A cost-effectiveness model of tibolone as treatment for the prevention of osteoporosis fractures in postmenopausal women in Sweden. Clin Drug Invest 21:115–127CrossRef Willis M, Odegaard K, Persson U, Mellstrom D, et al (2001) A cost-effectiveness model of tibolone as treatment for the prevention of osteoporosis fractures in postmenopausal women in Sweden. Clin Drug Invest 21:115–127CrossRef
73.
Zurück zum Zitat Willis M (2002) The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden. Int J Technol Assess Health Care 18:791–807CrossRefPubMed Willis M (2002) The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden. Int J Technol Assess Health Care 18:791–807CrossRefPubMed
Metadaten
Titel
Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature
verfasst von
Rachael L. Fleurence
Cynthia P. Iglesias
David J. Torgerson
Publikationsdatum
01.01.2006
Verlag
Springer-Verlag
Erschienen in
Osteoporosis International / Ausgabe 1/2006
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-005-1943-z

Weitere Artikel der Ausgabe 1/2006

Osteoporosis International 1/2006 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärztinnen und Psychotherapeuten.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.